Subscribe by Email

Your email:


schedule appointment now

describe the image

Dr. Starpoli's Blog

Current Articles | RSS Feed RSS Feed

50% Rise in Esophageal Cancer in Britain

  
  
  

esophageal cancer pic resized 600Esophageal cancer rates have risen by 50% over the past 25 years in men in the United Kingdom, according to new figures released by Cancer Research UK.

As well as a dramatic increase in incidence, there has been a change in the histology of the cancer, with most cases now being adenocarcinoma instead of squamous cell carcinoma (SCC). 

The latest British figures show that 5100 men were diagnosed with esophageal cancer in 2007, compared with 2600 men in 1983.

The incidence rate is now 14.4 per 100,000 men, which is 50% higher than the rate of 9.6 per 100,000 men in 1983. The most dramatic rise was in men in their 50s, in whom the rate was increased by 67%.

Esophageal cancer has also increased in women, but not as dramatically; there was an 8% increase from 1983 to 2007 (55.1 to 5.5 per 100,000).

Similarly, the incidence of adenocarcinoma has increased by about 350% in the past 30 years in the United States. The disease seems to be "attacking" middle-aged white males in our country. 

The reasons behind these increases in esophageal cancer is unclear. Central obesity has certainly increased over the past several decades and obesity is a significant risk factor for reflux. During reflux, the stomach contents migrate up into the esophagus and bathe the esophageal walls in acid and nonacid injurious juices. The chronic damage causes cells to turn over in an abnormal manner producing precancerous cells referred to as intestinal metaplasia. Intestinal metaplasia is also called Barrett's Esophagus and portends a higher risk for the development of esophageal cancer.

Anthony A. Starpoli, MD | www.starpoli.com

Comments

Dr. Starpoli accurately points out the fact that adenocarcinoma of the lower esophagus has bee increasing dramatically for the last 30 years. 35 years ago I wrote a paper on esophageal cancer for a residency project. At that time adenocarcinoma was "a footnote" compared to squamous cell cancer an now it is the dominant form of this deadly disease. It is true that reflux is a major component, but what hasn't been studied, and likely won't be studied because pharmaceutical companies fund most of the research, is the impact that acid suppression medications have on the development of adenocarcinoma. Gastric acid is present naturally and it has been speculated to have a protective effect by denaturing certain carcinogenic chemical, nitrosomenes, that are present in the food we eat. When the acid is effectively shut-off by the powerful acid reducers now being taken by some 30 million Americans, these carcinogens may remain unaltered. The only evidence that exists to support this theory is the fact that the incidence of adenocarcinoma of the distal esophagus was quite low and relatively stable undtil the mid to late 1970's when it began to rise and has continued to do so at an almost logrhythmic pace. While it is true that obesity has been on the rise through out the last half of the twentieth century and the fisrt decade of the twenty-first, it seems more than just coincidental that Tagomet, the first "acid blocker" was introduced in 1974 and was followed by a plethora of other powerful acid blockers which until very recently were widely prescribed with little concern for long term side effects. Now evidence has surfaced to link some of these drugs, the PPIs, with osteoporosis, but thus far there has been no research that I'm aware of to study the possible relationship between H2 blockers and PPIs and the rising incidence of one of the deadliest forms of GI cancer, I suspect we will continue to see adenocarcinoma of the esophagus. 
I congratulate Dr. Starpoli for bringing the significant issue to everyone's attention. 
 
Robert Sewell, MD, FACS
Posted @ Sunday, October 17, 2010 9:44 AM by Robert Sewell
Comments have been closed for this article.